(Reuters)—Anthem Inc. said on Friday it would buy Cigna Corp. in a deal valued at $54.2 billion, creating the largest U.S. health insurer by membership. The deal—the biggest ever in the health insurance industry—comes three weeks after Aetna Inc agreed to buy Humana Inc for $37 billion and is part of an industry-wide consolidation following…
Search results for: hip OA
Most Rheumatologists Want FDA to Better Regulate Biosimilars
In a survey, the Coalition of State Rheumatology Organizations found a consensus among rheumatologists that the FDA should increase safety for biosimilar therapies via naming and labeling regulations…
Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website
In a 25 month Phase 3 trial, abaloparatide-SC reduced the risk of new fractures in patients suffering from postmenopausal osteoporosis. Plus, the FDA launches a new drug safety website.
Tofacitinib Not Tied to More Malignancies in RA Patients
NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) does not increase the risk of malignancies, according to pooled data from more than 5000 rheumatoid arthritis (RA) patients. In an April 22 online paper in Annals of the Rheumatic Diseases, Dr. Lisy Wang of Pfizer, Groton, Connecticut, and colleagues noted that in RA…
Teriparatide to Denosumab Switch Helpful in Osteoporosis
NEW YORK (Reuters Health)—In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. In a July 3 online paper in The Lancet, Dr. Benjamin Z. Leder, of Massachusetts General Hospital, Boston, and colleagues noted that many…
Secukinumab Effective for Treating Psoriatic Arthritis
NEW YORK (Reuters Health)—The anti-interleukin-17A monoclonal antibody secukinumab improves signs and symptoms in patients with psoriatic arthritis, according to results from Novartis’ FUTURE 2 trial. In earlier studies, secukinumab has demonstrated superior effectiveness to placebo and etanercept in improving the signs and symptoms of psoriasis. Dr. Iain B. McInnes from the University of Glasgow in…
Prepare NOW for ICD-10 Medical Coding Transition
The ICD-10 page on the Centers for Medicare & Medicaid Services (CMS) website features a countdown clock that shows the time left until Oct. 1, 2015, the date on which compliance with the new code set becomes mandatory. By the time this issue goes to press, the clock will read 90 or fewer days. Time…
Healthcare Office Design Can Make a Positive Difference for Rheumatology Patients
When designing healthcare spaces to foster wellness, you should first understand the particular patient illness being served and then determine that population’s fundamental needs. “Providers who serve patients with rheumatoid conditions should identify the range of clinical presentations specific to their patient population,” advises Sharon E. Woodworth, AIA, ACHA, EDAC, Healthcare Practice Leader, Perkins+Will Architects,…
How to Launch Successful Rheumatology Patient Advocacy Programs
Editor’s note: This is the second installment of a two-part series showing how a busy office-based practice can incorporate patient advocacy into its standard workflow. In Part 1, we looked at the reasons for incorporating patient advocacy into your practice and offered an outline for implementing it. Part 2 amplifies the concepts explored in Part…
How to Deliver Difficult News about Patients’ Diagnoses
Telling a patient that he or she has been diagnosed with rheumatoid arthritis (RA), ankylosing spondylitis, fibromyalgia or another debilitating, painful and/or chronic condition can be upsetting for a patient to hear and difficult for a rheumatologist to convey. Given this, it’s important to prepare for the appointment. “Take a few minutes beforehand to contemplate…
- « Previous Page
- 1
- …
- 238
- 239
- 240
- 241
- 242
- …
- 329
- Next Page »